| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARHGAP29 |
| Uniprot No | Q52LW3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1261aa |
| 氨基酸序列 | MIAHKQKKTKKKRAWASGQLSTDITTSEMGLKSLSSNSIFDPDYIKELVNDIRKFSHMLLYLKEAIFSDCFKEVIHIRLEELLRVLKSIMNKHQNLNSVDLQNAAEMLTAKVKAVNFTEVNEENKNDLFQEVFSSIETLAFTFGNILTNFLMGDVGNDSLLRLPVSRETKSFENVSVESVDSSSEKGNFSPLELDNVLLKNTDSIELALSYAKTWSKYTKNIVSWVEKKLNLELESTRNMVKLAEATRTNIGIQEFMPLQSLFTNALLNDIESSHLLQQTIAALQANKFVQPLLGRKNEMEKQRKEIKELWKQEQNKMLEAENALKKAKLLCMQRQDEYEKAKSSMFRAEEEHLSSSGGLAKNLNKQLEKKRRLEEEALQKVEEANELYKVCVTNVEERRNDLENTKREILAQLRTLVFQCDLTLKAVTVNLFHMQHLQAASLADSLQSLCDSAKLYDPGQEYSEFVKATNSTEEEKVDGNVNKHLNSSQPSGFGPANSLEDVVRLPDSSNKIEEDRCSNSADITGPSFIRSWTFGMFSDSESTGGSSESRSLDSESISPGDFHRKLPRTPSSGTMSSADDLDEREPPSPSETGPNSLGTFKKTLMSKAALTHKFRKLRSPTKCRDCEGIVVFQGVECEECLLVCHRKCLENLVIICGHQKLPGKIHLFGAEFTQVAKKEPDGIPFILKICASEIENRALCLQGIYRVCGNKIKTEKLCQALENGMHLVDISEFSSHDICDVLKLYLRQLPEPFILFRLYKEFIDLAKEIQHVNEEQETKKNSLEDKKWPNMCIEINRILLKSKDLLRQLPASNFNSLHFLIVHLKRVVDHAEENKMNSKNLGVIFGPSLIRPRPTTAPITISSLAEYSNQARLVEFLITYSQKIFDGSLQPQDVMCSIGVVDQGCFPKPLLSPEERDIERSMKSLFFSSKEDIHTSESESKIFERATSFEESERKQNALGKCDACLSDKAQLLLDQEAESASQKIEDGKTPKPLSLKSDRSTNNVERHTPRTKIRPVSLPVDRLLLASPPNERNGRNMGNVNLDKFCKNPAFEGVNRKDAATTVCSKFNGFDQQTLQKIQDKQYEQNSLTAKTTMIMPSALQEKGVTTSLQISGDHSINATQPSKPYAEPVRSVREASERRSSDSYPLAPVRAPRTLQPQHWTTFYKPHAPIISIRGNEEKPASPSAAVPPGTDHDPHGLVVKSMPDPDKASACPGQATGQPKEDSEELGLPDVNPMCQRPRLKRMQQFEDLEGEIPQFV |
| 预测分子量 | 142 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ARHGAP29重组蛋白的模拟参考文献(信息为示例，非真实文献)：
1. **标题**: *"Recombinant ARHGAP29 protein inhibits RhoA signaling and regulates epithelial cell migration"*
**作者**: Smith J, et al.
**摘要**: 研究报道了重组ARHGAP29蛋白的体外功能，证实其通过水解RhoA-GTP抑制下游信号通路，进而调节上皮细胞的迁移能力，为癌症转移机制提供了新见解。
2. **标题**: *"Expression and purification of functional ARHGAP29 in E. coli for structural analysis"*
**作者**: Zhang L, et al.
**摘要**: 本文描述了一种高效表达和纯化重组ARHGAP29蛋白的方法，通过大肠杆菌系统获得高纯度蛋白，并利用X射线晶体学解析其催化结构域的三维结构。
3. **标题**: *"ARHGAP29 modulates TGF-β-induced cytoskeletal remodeling in fibrosis development"*
**作者**: Lee S, et al.
**摘要**: 研究发现重组ARHGAP29蛋白可干预TGF-β信号通路，通过抑制RhoA/ROCK通路减少肌成纤维细胞活化，提示其在抗纤维化治疗中的潜在应用。
4. **标题**: *"ARHGAP29 deficiency disrupts embryonic neural tube closure via dysregulated actomyosin contractility"*
**作者**: Chen R, et al.
**摘要**: 利用重组ARHGAP29蛋白进行功能挽救实验，揭示了其在胚胎神经管发育中通过调控细胞骨架张力维持组织完整性的关键作用。
(注：以上文献为示例性内容，实际研究中请通过学术数据库检索真实文献。)
ARHGAP29 is a member of the Rho GTPase-activating protein (RhoGAP) family, which plays a critical role in regulating Rho GTPases, particularly RhoA. These proteins function as molecular switches, cycling between active GTP-bound and inactive GDP-bound states to control cytoskeletal dynamics, cell adhesion, migration, and polarity. ARHGAP29 specifically accelerates the hydrolysis of GTP to GDP on RhoA, thereby inactivating it. This activity modulates downstream signaling pathways involved in cellular processes such as stress fiber formation, focal adhesion assembly, and actomyosin contractility. Dysregulation of ARHGAP29 has been implicated in pathological conditions, including cancer metastasis, cardiovascular diseases, and fibrotic disorders, highlighting its importance in maintaining tissue homeostasis.
Recombinant ARHGAP29 protein is engineered for experimental studies to elucidate its molecular mechanisms and interactions. Produced through heterologous expression systems (e.g., bacterial, insect, or mammalian cells), the recombinant protein retains functional domains, such as the RhoGAP catalytic domain and pleckstrin homology (PH) domain, which mediate its localization and activity. Purification techniques like affinity chromatography ensure high specificity and yield. Researchers utilize this protein in vitro to study its binding partners, enzymatic kinetics, and structural features. It also serves as a tool to inhibit RhoA signaling in cellular assays, enabling investigations into ARHGAP29's role in processes like endothelial barrier function, epithelial morphogenesis, or cancer cell invasion.
The development of ARHGAP29 recombinant protein has advanced both basic and translational research. Its applications range from drug discovery targeting RhoA-dependent pathways to understanding developmental biology. Studies using this protein have revealed its context-dependent roles—for example, acting as a tumor suppressor in certain cancers while promoting fibrosis in others. Additionally, ARHGAP29 polymorphisms are linked to susceptibility to cleft palate and vascular anomalies, underscoring its diverse physiological relevance. By providing a controlled, pure protein source, recombinant ARHGAP29 facilitates mechanistic insights and therapeutic exploration in diseases associated with Rho signaling dysregulation.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
